1 recruiting, 1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Renske Altena: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC Positron emission tomografy with [68Ga]Ga-ABY-025 - Breast Cancer Stage IV, HER2-low Breast Cancer | Recruiting | Renske Altena | 70 | 2025-10-03 | 2025-11-20 | |
| Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Docetaxel, Carboplatin, Trastuzumab - Early-stage Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Terminated | Renske Altena | 6 | 2019-05-23 | 2021-09-23 |
Breast Neoplasms (2)
Ado-Trastuzumab Emtansine (1) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Epirubicin (1) · Paclitaxel (1) · Trastuzumab (1) · atezolizumab (1) · pertuzumab (1)
Sweden (2)
2018 (1)